Enoxaparin ͉ neurodegeneration ͉ transgenic mouse ͉ mitochondria ͉ Lovenox H untington's disease (HD) has onset usually between 35 and 50 years with chorea and psychiatric disturbances and gradual but inexorable intellectual decline to death after 15-20 years (1). Neuropathological analysis reveals selective and progressive neuronal loss in the striatum (1), particularly affecting the GABAergic medium spiny neurons (MSN). At the molecular level, the cause of HD is a polyglutamine expansion (exp) in the amino terminus of huntingtin (Htt), a 350-kDa ubiquitously expressed cytoplasmic protein (2). Despite significant progress, cellular mechanisms that link the Htt exp mutation with the disease are poorly understood (3).
Enoxaparin ͉ neurodegeneration ͉ transgenic mouse ͉ mitochondria ͉ Lovenox H untington's disease (HD) has onset usually between 35 and 50 years with chorea and psychiatric disturbances and gradual but inexorable intellectual decline to death after 15-20 years (1) . Neuropathological analysis reveals selective and progressive neuronal loss in the striatum (1) , particularly affecting the GABAergic medium spiny neurons (MSN). At the molecular level, the cause of HD is a polyglutamine expansion (exp) in the amino terminus of huntingtin (Htt), a 350-kDa ubiquitously expressed cytoplasmic protein (2) . Despite significant progress, cellular mechanisms that link the Htt exp mutation with the disease are poorly understood (3) .
A number of transgenic HD mouse models have been generated that reproduce many HD-like features (4) . In the yeast artificial chromosome (YAC128) mouse model, the full-length human Htt protein with polyglutamine exp (128Q) is expressed under the control of its endogenous promoter and regulatory elements (5) . The onset of a motor deficit before striatal neuronal loss in the YAC128 mouse model accurately recapitulates the progression of HD (5) . Thus, the YAC128 mouse model is ideal for understanding the cellular mechanisms that lead to neurodegeneration in HD, as well as for validating potential therapeutic agents.
Previous studies demonstrated that Htt exp facilitates activity of the NR2B subtype of NMDA receptors (NMDARs) (6-8) and the type 1 inositol 1,4,5-trisphosphate receptors (InsP 3 R1) (9) . A connection between disturbed Ca 2ϩ signaling and neuronal apoptosis is well established (10, 11) , and we therefore proposed that Htt exp -induced Ca 2ϩ overload results in degeneration of MSN in HD (12) . To test this hypothesis, we analyzed Ca 2ϩ signals and apoptotic cell death in primary cultures of MSN from the YAC128 mice. Our results provide further support to the hypothesis that disturbed Ca 2ϩ underlies neuronal cell death in HD (12) and allowed us to identify a number of potential therapeutic targets for HD treatment.
Materials and Methods
Primary Neuronal Cultures. Generation and breeding of YAC18 and YAC128 transgenic mice (FVBN͞NJ background strain) are described in refs. 5 and 13. Heterozygous male YAC128 or YAC18 mice were crossed with the wild-type (WT) female mice and resulting litters were collected at postnatal days 1-2. The pups were genotyped by PCR with primers specific for exons 44 and 45 of human Htt gene and the medium spiny neuronal (MSN) or hippocampal neuronal (HN) cultures of WT, YAC18, and YAC128 mice were established and maintained as described in ref. 9 .
Ca 2؉ Imaging Experiments. Fura-2 Ca 2ϩ imaging experiments with 14-to 16-DIV (days in vitro) MSN cultures were performed as described in ref. 9 , using a DeltaRAM illuminator, an IC-300 camera, and IMAGEMASTER PRO software (all from PTI, South Brunswick, NJ). The cells were maintained in artificial cerebrospinal fluid (aCSF) (140 mM NaCl͞5 mM KCl͞1 mM MgCl 2 ͞2 mM CaCl 2 ͞10 mM Hepes, pH 7.3) at 37°C during measurements (PH1 heater, Warner Instruments, Hamden, CT). Fura-2 340͞ 380 ratio images were collected every 6 sec for the duration of the experiment. Baseline (1-3 min) measurements were obtained before first pulse of glutamate. The 20 M glutamate solution was dissolved in aCSF and 1-min pulses of 37°C glutamate solution (SH-27B in-line solution heater, Warner Instruments) were applied by using a valve controller (VC-6, Warner Instruments) driven by a square-pulse electrical waveform generator (Model 148A, Wavetek, San Diego). DHPG (3,5-dihydroxyphenylglycine)-induced Ca 2ϩ responses have been measured in Ca 2ϩ -free aCSF (omitted CaCl 2 from aCSF and supplemented with 100 M EGTA). For the Enoxaparin experiments, MSN were preincubated in medium containing 200 g͞ml Enoxaparin for 3 h. Enoxaparin was included at 200 g͞ml in all solutions during Fura-2 loading and Ca 2ϩ imaging steps.
TUNEL Staining Experiments. The 14-DIV MSN or HN were exposed for 8 h to a range of glutamate concentrations added to the culture medium. During exposure to glutamate, the cells were maintained in a cell culture incubator (humidified 5% CO 2 , 37°C). (ϩ)MK-801, ifenprodil, MPEP [2-methyl-6-(phenylethynyl)pyridine hydrochloride], CPCCOEt {7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylate ethyl ester}, and Ruthenium (Ru) 360 were added to cell culture media 30 min before the addition of glutamate. 2-APB, Enoxaparin, Z-VAD-FMK, Z-FA-FMK, Z-DEVD-FMK, Z-LEHD-FMK, Z-IETD-FMK, bongkrekic acid, Nortriptyline, Pirenzepine, Promethazine, Desipramine, Trifluoperazine, Thiothixene, and Maprotiline were added 2-3 h before glutamate exposure. Immediately after exposure to glutamate, neurons were fixed for 30 min in 4% paraformaldehyde plus 4% sucrose in PBS (pH 7.4), permeabilized for 5 min in 0.25% Triton X-100, and stained by using the DeadEnd Fluorometric TUNEL System (Promega) according to the manufacturer's instructions. Nuclei were counterstained with 5 M propidium iodide (PI) (Molecular Probes). Coverslips were extensively washed with PBS and mounted in Mowiol 4-88 (Polysciences). FITC-and PI-fluorescent images were collected with an Olympus IX70 microscope with ϫ40 objectives, using a Cascade:650 camera (Roper Scientific) and METAFLUOR software (Universal Imaging, Downingtown, PA). Four to six randomly chosen microscopic fields containing 200-300 MSN were captured, and the number of TUNEL-positive neuronal nuclei was calculated as a fraction of PI-positive neuronal nuclei in each microscopic field by an observer blinded to the nature of the sample. Nuclei of glial cells, identified by large size and weak PI staining, were not counted in the analysis. The fractions of TUNEL-positive nuclei determined for each microscopic field were averaged, and the results are presented as means Ϯ SD (n ϭ number of fields counted).
Planar Lipid Bilayer Experiments. Single-channel recordings of rat cerebellar InsP 3 R1 were performed as described in ref. 14. Briefly, rat cerebellar microsomes were isolated by differential centrifugation and fused to planar lipid bilayers. The activity of InsP 3 -gated channels was recorded at a 0-mV transmembrane potential by using 50 mM Ba 2ϩ (trans) dissolved in Hepes (pH 7.35) as a charge carrier. The cis (cytosolic) chamber contained 110 mM Tris dissolved in Hepes (pH 7.35), 0.5 mM Na 2 ATP, and pCa 6.7 (0.2 mM EGTA plus 0.14 mM CaCl 2 ). Cerebellar InsP 3 R1 was activated by addition of 2 M InsP 3 (Alexis) to the cis chamber. Different concentrations of Enoxaparin were added to the cis chamber. The InsP 3 -gated currents were amplified (OC-725, Warner Instruments), filtered at 1 kHz by low-pass 8-pole Bessel filter, digitized at 5 kHz (Digidata 1200, Axon Instruments), and stored on a computer hard drive and optical discs. For off-line computer analysis (PCLAMP 6, Axon Instruments), currents were filtered digitally at 500 Hz. For presentation of the current traces, data were filtered at 200 Hz.
Cytochrome c Release Assay. MSN cultures at 12-to 14-DIV were exposed to glutamate for 5 h, washed once with PBS, scraped off in the homogenization buffer (0.32 M sucrose͞25 mM Hepes, pH 8.0͞1 mM EDTA͞1 mM DTT͞protease inhibitors), homogenized, and clarified by a 60-min spin at 100,000 ϫ g. The supernatant was collected as the soluble fraction, and the protein concentration of each sample was determined by using a BioRad protein assay kit. Both pellet and supernatant were lysed in SDS-loading buffer and boiled. Samples were resolved by SDS͞ PAGE, analyzed by Western blotting with anti-cytochrome c monoclonal antibody (BD Pharmingen), and quantified by densitometry.
Drugs. Ru360 and 2-APB were from Calbiochem. Glutamate, MPEP, CPCCOEt, (ϩ)-MK801 maleate, and ifenprodil were purchased from Tocris. Z-VAD-FMK, Z-FA-FMK, Z-DEVD-FMK, Z-LEHD-FMK, and Z-IETD-FMK were from R & D Systems. Bongkrekic acid, Nortriptyline, Pirenzepine, Promethazine, Desipramine, Trifluoperazine, Thiothixene, and Maprotiline were from Sigma-Aldrich.
Results
Disturbed Ca 2؉ Signals in YAC128 MSN. Previous findings (6) (7) (8) (9) suggested that glutamate should induce supranormal Ca 2ϩ responses in HD MSN. To test this hypothesis, we compared glutamate-induced Ca 2ϩ signals in MSN primary cultures established from the WT, YAC18 (13) , and YAC128 (5) mice. To mimic physiological conditions more closely, we applied repetitive pulses of 20 M glutamate 1 min in duration, followed by a 1-min washout (Fig. 1) . The intracellular Ca 2ϩ concentration in these experiments was continuously monitored by Fura-2 imaging, and the data were presented as 340͞380 ratios (Fig. 1) . On average, basal Ca 2ϩ levels before glutamate application were not significantly different from each other for all three groups of MSN (Fig. 1D) . Thus, increase in basal rat and mouse MSN Ca 2ϩ levels as a result of Htt overexpression observed in our previous experiments (9, 15) most likely results from high levels of Htt expression in transfected MSN. Repetitive pulses of glutamate caused large elevation of Ca 2ϩ levels in the YAC128 MSN (Fig.  1C) , versus much smaller Ca 2ϩ increases in the WT (Fig. 1 A) and YAC18 (Fig. 1B) MSN. On average, Ca 2ϩ levels after 20 pulses of glutamate were not significantly different between WT and YAC18 MSN but were significantly (P Ͻ 0.05) higher in YAC128 MSN when compared with either WT or YAC18 MSN (Fig. 1D) .
In Vitro HD Model. Next, we established an ''in vitro HD'' model that reproduces Htt exp -dependent degeneration of MSN. These experiments were performed with primary cultures of WT, YAC18, and YAC128 MSN. At 14 DIV, all three groups of MSN were challenged by an 8-h application of glutamate (from 0 to 250 M) to mimic physiological stimulation. After exposure to glutamate, MSN were fixed, permeabilized, and scored for apoptotic cell death by using TUNEL staining. We determined that, in basal conditions (no glutamate added), Ϸ10% of MSN in all three experimental groups were apoptotic (TUNELpositive) (Figs. 2 A and B) . Addition of 25 or 50 M glutamate increased the number of apoptotic cells to 15-20% in all three experimental groups (Figs. 2 A and B) . Addition of 100 or 250 M glutamate increased apoptotic death to 60 -70% for YAC128 MSN (Figs. 2 A and B) but only to 25-30% for WT and YAC18 MSN (Figs. 2 A and B) . Thus, we reasoned that exposure to glutamate concentrations in the 100-250 M range leads to selective apoptosis of YAC128 MSN. As an additional control for specificity of observed degeneration, we compared glutamate-induced apoptosis in primary cultures of WT and YAC128 hippocampal neurons (HN), which are spared in HD (1) . No significant differences in apoptosis of HN from WT and YAC128 mice in the 0-500 M range of glutamate concentrations (8-h exposure) were apparent (data not shown).
Disturbed Ca 2؉ Signaling and Degeneration of MSN in HD. To test the connection between disturbed Ca 2ϩ signaling (Fig. 1 ) and glutamate-induced degeneration of YAC128 MSN (Fig. 2) , we assessed the previously described ''in vitro HD'' assay in the presence of Ca 2ϩ signaling blockers. We found that inhibition of mGluR1͞5 receptors (by a mixture of MPEP and CPCCOEt) reduced the glutamate-induced apoptosis of YAC128 MSN to WT MSN levels (Fig. 3A) . Inhibition of the NMDAR by (ϩ)MK801 had a similar neuroprotective effect (data not shown). The NR2B-specific antagonist ifenprodil also decreased glutamate-induced apoptosis of YAC128 MSN to WT MSN levels (Fig. 3B) . A combination of mGluR1͞5 and NMDAR blockers [MPEP, CPCCOEt, and (ϩ)MK801] completely eliminated glutamate-dependent apoptotic cell death in both WT and YAC128 MSN (Fig. 3C) . In a previous study, we demonstrated that InsP 3 R1-mediated Ca 2ϩ release is potentiated in MSN transfected with Htt exp expression plasmids (9) . Consistent with direct involvement of InsP 3 R1, preincubation of the MSN cultures with a membrane-permeable InsP 3 R blocker 2-APB (16) protected YAC128 MSN from glutamate-induced apoptosis (Fig. 3D) .
Because InsP 3 R1 appears to be involved in the glutamateinduced apoptosis of YAC128 MSN (Fig. 3D) , we hypothesized that InsP 3 R1 might be a potential drug target for HD treatment. Bath application of a low-molecular-weight heparin sulfate Enoxaparin (Lovenox) prevents glutamate-induced Ca 2ϩ release in cerebellar slices, presumably by blocking InsP 3 R1 activity (17) . To directly test the ability of Enoxaparin to block InsP 3 R1, we performed a series of planar lipid bilayer reconstitution experiments with rat cerebellar microsomes.
Addition of Enoxaparin efficiently and reversibly inhibited InsP 3 R1 in planar lipid bilayers (Fig. 4A) , similar to actions of a high-molecular-weight heparin. Quantitative analysis of the inhibitory effects of Enoxaparin on InsP 3 R1 yielded an IC 50 of 50 ng͞ml and a Hill coefficient of 3.4 (Fig. 4B) , consistent with Enoxaparin binding to each subunit of the InsP 3 R1 tetramer. To establish that Enoxaparin is able to block InsP 3 R1 in striatal MSN, we performed a series of Ca 2ϩ imaging experiments with Fura-2. As described in ref. 9 , application of 25 M DHPG induced Ca 2ϩ release in cultured MSN in Ca 2ϩ -free medium (Fig. 4C) . Preincubation with 200 g͞ml Enoxaparin for 3 h prevented DHPG-induced Ca 2ϩ release in cultured MSN (Fig. 4D) , consistent with the ability of Enoxaparin to permeate cell membranes (17) and block InsP 3 R1 activity (Figs. 4 A and B) . Using the ''in vitro HD'' assay, we found that 200 g͞ml Enoxaparin protected YAC128 MSN from gluta- mate-induced apoptosis (Fig. 4E) , consistent with 2-APB data (Fig. 3D) .
Intrinsic Apoptotic Pathway, Mitochondria, and HD MSN Degeneration. Which apoptotic pathway is involved in glutamate-induced degeneration of HD MSN? Preincubation with the pan-caspase membrane-permeable inhibitor (Z-VAD-FMK), but not with the control peptide (Z-FA-FMK), reduced glutamate-induced apoptosis of YAC128 MSN to WT levels (Fig. 5A) . Thus, apoptosis of YAC128 MSN occurs via a caspase-dependent pathway. Membrane-permeable inhibitors of caspase-3 (Z-DEVD-FMK) and caspase-9 (Z-LEHD-FMK) also protected YAC128 MSN from glutamate-induced apoptosis (Figs. 5 B and  C) . In contrast, a membrane-permeable inhibitor of caspase-8 (Z-IETD-FMK) was ineffective (Fig. 5D) . These results are consistent with glutamate-induced apoptosis of YAC128 MSN occurring via the intrinsic (mitochondria and caspase-9-mediated) and not via the extrinsic (death receptor and caspase-8-mediated) pathway.
Activation of an intrinsic apoptotic pathway requires release of cytochrome c from the intramitochondrial space into the cytoplasm (10, 11) . When WT MSN were incubated with 100 or 250 M of glutamate for 5 h, a small elevation in cytosolic cytochrome c levels was observed (Fig. 5E) . In contrast, a 5-h incubation of YAC128 MSN with 250 M glutamate resulted in a much larger increase of cytosolic cytochrome c signal (Fig. 5E ). These data are consistent with the activation of the intrinsic apoptotic pathway in YAC128 MSN but not in WT MSN, as a result of exposure to 250 M glutamate in our experiments (Figs.  2 A and B) .
Whether disturbed cytosolic Ca 2ϩ signaling in YAC128 MSN (Figs. 1 C and D) is linked to the release of cytochrome c from the innermitochondrial space (Fig. 5E ) is unknown. It is well established that excessive cytosolic Ca 2ϩ is efficiently taken up by the mitochondria via activity of the mitochondrial Ca 2ϩ uniporter͞channel (MCU) located in the mitochondria inner membrane (18) . Consistent with involvement of MCU in our experiments, preincubation of MSN with the membranepermeable MCU blocker Ru360 (18, 19) reduced the glutamateinduced apoptotic cell death of YAC128 MSN to WT MSN levels (Fig. 5F ).
It has been proposed that mitochondrial Ca 2ϩ overload leads to release of cytochrome c due to opening of the mitochondrial permeability transition pore (MPTP) (10, 11) . Consistent with the role of MPTP, we demonstrated that preincubation with the 10 M MPTP inhibitor bongkrekic acid (BKA) (20) reduced glutamate-induced apoptosis of YAC128 MSN to WT levels (Table 1) . Recently, a number of biologically active Food and Drug Administration-approved heterocyclic, tricyclic, and phenothiazine-derived compounds have been identified as putative MPTP blockers (21) . To determine the potential usefulness of these compounds for HD, we performed ''in vitro HD'' assay experiments with compounds from this class. We found that preincubation with 2 M Nortriptyline, Desipramine, Trifluoperazine, or Maprotiline protected YAC128 MSN from glutamate-induced apoptosis (Table 1) , consistent with their putative MPTP-blocking activity (21) . As a control for specificity of observed effects, we demonstrated that Pirenzepine and Thiothixene were not protective (Table 1) , despite similarity in chemical structure. in HD (Fig. 6) . Specifically, we propose that glutamate released from corticostriatal projection neurons stimulates NR1͞NR2B NMDAR and mGluR5 receptors, both of which are abundantly expressed in the striatal MSN (22, 23 (9) , stimulating NR1͞NR2B NMDAR activity (6) (7) (8) , and directly destabilizing mitochondrial Ca 2ϩ handling (24, 25) . As a result, stimulation of glutamate receptors results in supranormal Ca 2ϩ responses in HD MSN, leading to cytosolic Ca 2ϩ overload (Fig. 6) . Excessive cytosolic Ca 2ϩ is taken into the mitochondria via activity of the MCU (Fig.  6 ). With time, mitochondrial Ca 2ϩ storage capacity is exceeded, leading to an opening of MPTP, release of cytochrome c into the cytosol, and activation of the caspase-mediated intrinsic apoptotic program (Fig. 6 ). These observations suggest that delayed onset of MSN degeneration in HD is at least in part a result of significant mitochondrial Ca 2ϩ storage capacity that takes a long time to exceed, as we previously speculated (12) . Consistent with mitochondrial involvement is the observation of dysfunctional mitochondria in HD mouse models and in HD patients (24, 25) . The abnormal cytosolic and mitochondrial Ca 2ϩ levels may contribute to neurological abnormalities observed in early-grade HD patients and in HD mouse models before onset of neurodegeneration.
Discussion
Potential Therapeutic Targets for Treatment of HD. The proposed model (Fig. 6 ) may have implications for the treatment of HD. Our results suggest that NR2B NMDAR (Fig. 3B ) and mGluR5 (Fig. 3A) can be considered potential drug targets for HD treatment. We have also demonstrated that inhibition of InsP 3 R1 by 2-APB (Fig. 3D) , inhibition of MCU by Ru360 (Fig. 5F ), and inhibition of MPTP by bongkrekic acid (Table 1) reduced glutamate-induced apoptosis of YAC128 MSN to WT MSN levels. Thus, InsP 3 R1 and MPTP would appear to constitute therapeutic targets for HD. In our experiments, it was demonstrated that low-molecular-weight heparin Enoxaparin (Lovenox) exerts a neuroprotective effect on YAC128 MSN (Fig. 4E) , apparently by directly inhibiting InsP 3 R1 function (Figs. 4 A-D) . Intravenous injections of Enoxaparin are neuroprotective in animal models of stroke and neurodegenerative diseases (26) (27) (28) , and our results indicate that Enoxaparin may also be worthy of assessment as HD therapeutics. Recently, a number of biologically active Food and Drug Administrationapproved heterocyclic, tricyclic, and phenothiazine-derived compounds have been identified as putative MPTP blockers (21) . In our experiments, it is demonstrated that several members of this class of compounds (Nortriptyline, Desipramine, Trifluoperazine, and Maprotiline) protect YAC128 MSN from glutamate-induced apoptosis (Table 1 ). Future studies with animal models of HD or human clinical trials will be required to test the utility of putative MPTP blockers as potential therapeutics for HD. The potential side effects of these compounds, such as bleeding potential for Enoxaparin and anticholinergic actions of Nortriptyline and Desipramine, must be considered in the clinical setting.
